Great West Life Assurance CO Macrogenics Inc Transaction History

Great West Life Assurance CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$9.77 - $21.47 $34,273 - $75,316	3,508 New	3,508 $52,000
Q3 2022 Nov 01, 2022	BUY	$3.01 - $5.22 $41,610 - $72,161	13,824 Added 446.66%	16,919 $59,000
Q2 2022 Aug 12, 2022	BUY	$2.25 - $9.99 $6,963 - $30,919	3,095 New	3,095 $9,000
Q2 2022 Aug 09, 2022	SELL	$2.25 - $9.99 $6,498 - $28,851	-2,888 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$8.12 - $16.9 $1,729 - $3,599	213 Added 7.96%	2,888 $27,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $3,197 - $4,397	201 Added 8.12%	2,675 $43,000
Q2 2021 Aug 11, 2021	SELL	$20.49 - $35.63 $16,166 - $28,112	-789 Reduced 24.18%	2,474 $66,000
Q3 2020 Nov 17, 2020	SELL	$24.69 - $31.6 $595,448 - $762,097	-24,117 Reduced 88.08%	3,263 $82,000
Q3 2020 Nov 13, 2020	BUY	$24.69 - $31.6 $595,448 - $762,097	24,117 Added 739.11%	27,380 $689,000
Q4 2019 Feb 11, 2020	BUY	$7.95 - $12.27 $25,940 - $40,037	3,263 New	3,263 $35,000
Q3 2019 Oct 25, 2019	SELL	$12.44 - $17.48 $77,314 - $108,638	-6,215 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$11.75 - $21.42 $43,651 - $79,575	3,715 Added 148.6%	6,215 $76,000
Q3 2017 Nov 09, 2017	BUY	$15.52 - $18.94 $38,800 - $47,350	2,500	2,500 $46,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

Stay updated on Great West Life Assurance CO with notifications on news.